ACET News and Press, Adicet Bio Inc. From 05/14/24

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of a poster presentation at the upcoming European Hematology Association (EHA) Hybrid Congr...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 2024 Ci...

2024-04-23 06:49:48 ET DENVER, Colo., Apr 23, 2024 ( 247marketnews.com )- Adicet Bio, Inc. (Nasdaq: ACET ) stated that a new preclinical data highlighting ADI-270 was selected for an oral presentation at the ASGCT 27th Annual Meeting on May 10, 2024 in the Targeted Gene and Cell The...

Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models ADI-270 demonstrated enhanced functional potency and resilience in tumor microenvironment On track to file an investigational new drug (IND) applicatio...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuit...

2024-03-21 16:58:21 ET Gainers: Adicet ( ACET ) +5% . The Honest Company ( HNST ) +5% . Sagimet Biosciences  ( SGMT ) +3% . National CineMedia ( NCMI ) +3% . Annexon  ( ANNX ) +3% . Losers: lululemon athletica&#...

2024-03-19 17:37:35 ET Gainers: Taysha Gene Therapies ( TSHA ) +32% . Canopy Growth Corporation ( CGC ) +14% . Sarcos Technology and Robotics ( STRC ) +12% . Adicet  ( ACET ) +6% . Bridger Aerospace Group Holdings ( BAER ) +4%...

2024-03-19 16:28:53 ET More on Adicet Bio Adicet Bio: Clinical Updates In H2 2024 Makes This A Must-Watch Jones upgrades Adicet to buy, cites upcoming catalysts Adicet Bio announces pricing of public offering Seeking Alpha’s Quant Rating on Adicet Bio ...

Expanded clinical pipeline into autoimmune diseases with U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug Application (IND) for ADI-001; initiation of Phase 1 clinical trial in lupus nephritis expected in 2Q 2024 On track to file IND for ADI-270 in renal cell ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the H.C...